



NSW
Therapeutic
Advisory
Group Inc.

Advancing
quality use
of medicines
in NSW

Fortnightly TAG Mail – resources list

10th April 2025

NSW TAG ACTIVITIES

Open email discussions

- Use of dupilumab for bullous pemphigoid: Do sites have a policy or treatment guideline formulated to treat this condition? Is any site observing increasing requests? Closes 16/4/2025

Recently completed email discussions

-Use of inpatient medicinal cannabis vapes

New NSW TAG publications

Medication Management Indicators for Residential Care Homes (RCHs)

Monash University and NSW TAG have developed a series of indicators, the MEGA-MAC Indicators, to measure the implementation of and adherence to the [Guiding Principles for Medication Management in Residential Aged Care Facilities](#). The MEGA-MAC indicators were developed as part of Monash University's Maximising Embedded Pharmacists in AGed CAre Medication Advisory Committees (MEGA-MAC) trial. The project is funded by the Commonwealth of Australia's 2022 Medical Research Future Fund (MRFF) Quality, Safety and Effectiveness of Medicine Use by Pharmacists grant. NSW TAG led the development of the indicators in consultation with Monash University and an expert steering group. Indicator specifications and data collection tools can be found at: <https://www.nswtag.org.au/residential-aged-care-facility-qum-indicators/>

Updated NSW TAG publications

- [SGLT2 inhibitor medicines for diabetes – Consumer information leaflet](#) (Version 3, March 2025)

Upcoming NSW TAG meeting dates

-NSW TAG Management Committee 14th April 2025
-NSW TAG General Members' Meeting 15th May 2025 2.30-4pm

Contact Sasha Bennett at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

CATAG Webinar: Empowering patients: Tools for understanding medicines governance

The webinar is the culmination of the Collaborating with Consumers QUDTP project, and will discuss how the developed resources assist health professionals explain off-label medicines use, non-formulary high-cost treatments, medicines access programs and novel and emerging therapies to consumers.

The webinar will be held on **30th April between 1 and 2pm (AEST)**.

The registration link is: <https://tinyurl.com/medicinesgovernance>

Educating health professionals through a Knowledge Transfer Framework to reduce use of high-risk, and/or unnecessary medicines Project

Advertisements for two positions closing 16th April 2025:

Research fellow (A/B) - Centre for Medicine Use and Safety- Monash Job board - [External](#)

Lecturer (Practice) level B - Centre for Medicine Use and Safety Monash Job board - [External](#)

EDITOR'S PICKS

AJHP: The impact of a customized eHR CDS tool on pharmacist renal dosing interventions - [link](#)

AJMQ: A Checklist to Improve Acute Stroke Evaluation and Treatment in the ED - [link](#)

AIM: Cannabis or Cannabinoids for the Management of CNCP - [link](#)

AIM: U.S. ED Visits Attributed by Clinicians to Semaglutide Adverse Events, 2022–2023 - [link](#)

BJCP: Education about deprescribing for pre-licensed and licensed healthcare professionals - [link](#)

BJCP: Best fit framework synthesis of qualitative studies on factors associated with medication nonadherence in people with T2DN using the COM-B model - [link](#)

BJCP: Typical complications with immunosuppressants in rheumatic disease- [link](#)
BJCP: Suspected adverse drug reactions in infants through breastfeeding - [link](#)
BJP: -Efficacy of pharmacological and non-pharmacological interventions for improving QoL of people with dementia - [link](#)
Cochrane: Withdrawal of antihypertensive drugs in older people - [link](#)
Cochrane: Effect of adrenergic agonist oral decongestants on blood pressure - [link](#)
DTB: Initiating renin–angiotensin system inhibitors in chronic kidney disease - [link](#)
EJHP: Improving patient outcomes during cancer drug shortages: the role of patient education - [link](#)
Health Canada: Systemic fluoropyrimidines and severe toxicity in patients with DPD deficiency - [link](#)
IMJ: -Advancements in multiple sclerosis - [link](#)
IJCP: DRPs experienced by RA patients during the first three months of methotrexate use- [link](#)
IJCP: Streamlining the quality assessment in medication reviews - [link](#)
IJCP: Screening tool to understand the medication habits of patients with swallowing difficulty- [link](#)
JAMA: IV Ferric Carboxymaltose in Heart Failure with Iron Deficiency - [link](#)
JAMA: Management of Staphylococcus aureus Bacteremia: A Review - [link](#)
JAMA Card: Encouraging Pharmacist Referrals for Evidence-Based Statin Initiation - [link](#)
JAMA IM: Inclusion of Retracted Studies in SRs and Meta-Analyses of Interventions- [link](#)
JAMA IM: Risk of Major Congenital Malformations Following Prenatal Exposure to Smoking Cessation Medicines - [link](#)
JAMA IM: Hospital Addiction Consultation Service and Opioid Use Disorder Treatment - [link](#)
JAMA Neur: Optimal Delay Time for Anticoagulation After Ischemic Stroke in Atrial Fibrillation- [link](#)
JAMA Onc: Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma - [link](#)
JCQPS: Implementation Science-Informed Strategies to Improve ToC for VTE- [link](#)
JCQPS: Safety Interventions in Cardiac Anesthesia: A Systematic Review - [link](#)
Lancet ID: Management of CMV in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies - [link](#)
Lancet Onc: Non-ICANS neurological complications after CAR T-cell therapies - [link](#)
Lancet RH: - 2024 AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin in adult neutropenic patients with solid tumours and hematological malignancies - [link](#)
Medsafe: Ayurvedic medicines update - [link](#)
MJA Perspective: Dismantling barriers to research and clinical care for vision impaired patients - [link](#)
MJA Editorial: Accountability for pharmaceuticals-related greenhouse gas emissions - [link](#)
NEJM: Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation - [link](#)
Paed: Monoclonal Antibodies for Pediatric Viral Disease Prevention and Treatment - [link](#)
Pharmacotherapy: Updates in chronic kidney disease management: A systematic review - [link](#)
PLOS Med: Pharmacogenetics and adverse drug reports- [link](#)
RCEM Advisory: Time Critical Medication Self- Administration in Emergency Departments - [link](#)
SPS: Using contraception with enzyme-inducing medicines - [link](#)
TGA: New safety warnings for isotretinoin ([Roaccutane](#)) - [link](#)
Thorax: - Use of inhaled corticosteroids in bronchiectasis - [link](#)

OTHER NEWS

NSW Health

- Measles alert for Sydney's Eastern Suburbs [[2 April 2025](#)]
- Public Health Warning: Nitazenes found in counterfeit oxycodone tablets in NSW [[28 March 2025](#)]
- Recognition and management of patients who are deteriorating ([PD2025_014](#)) [06 April 2025]
- Patient Admission and Discharge to NSW Health Facilities ([PD2025_012](#)) [26 March 2025]

TGA

- Updates to the Prescribing Medicines in Pregnancy database - [March 2025](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found [here](#)

- Synthetic oxytocin evidence brief - [link](#)

Australian Institute for Health and Welfare (AIHW)

- National Opioid Pharmacotherapy Statistics Annual Data collection annual report - [link](#)

MIMS monthly updates

- New Products

-- Momelotinib (as dihydrochloride monohydrate) ([Omijara](#)) for disease-related splenomegaly or symptoms in adults with moderate to severe anaemia who have primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis and who are JAK inhibitor naïve or have been treated with ruxolitinib. Omijara is contraindicated in pregnancy and breastfeeding.

- New Indications

-- Amivantamab ([Rybrevant](#)) - combination of carboplatin and pemetrexed for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor, and as first-line treatment of adults with locally advanced or metastatic NSCLC, with activating EGFR exon 20 insertion mutations

-- Dupilumab ([Dupixent](#)) - add-on maintenance treatment for uncontrolled COPD, characterised by raised blood eosinophils, in adults on a stable combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate

-- Durvalumab ([Imfinzi](#)) - monotherapy for the treatment of adults with limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy

-- Enfortumab vedotin ([Padcev](#)), in combination with pembrolizumab, for the first-line treatment of adult patients with locally advanced or metastatic urothelial cancer

-- Enzalutamide ([Xtandi](#)) for patients with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence at high-risk for metastasis

-- Nivolumab (rch) ([Opdivo](#)), in combination with platinum-doublet chemotherapy, for neoadjuvant treatment of adults with resectable (tumours ≥ 4 cm or node positive) non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, followed by Opdivo as a single agent in the adjuvant setting after surgical resection

-- Pembrolizumab (rch) ([Keytruda](#)), in combination with enfortumab vedotin, for the first-line treatment of adults with locally advanced or metastatic urothelial carcinoma; in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adults with primary advanced or recurrent endometrial carcinoma; and in combination with chemoradiotherapy, for the treatment of patients with high-risk, locally advanced cervical cancer (FIGO 2014 Stage IB2-IIB and node-positive, or Stage III-IVA)

PBS

- Expanded access to empagliflozin for type 2 diabetes patients with high cardiovascular risk - [1 April 2025](#)

- New Minimum Stockholding Requirements Online Notification Portal and Fact Sheet - [9 April 2025](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages

- AusPARs:

-- [Comirnaty JN.1](#) vaccine (Bretovameran), adapted to the SARS-CoV-2 Omicron JN.1 strain, has been approved to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 6 months of age and older

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

REPORTS AND PUBLICATIONS – INTERNATIONAL

Canadian Agency for Drugs and Technologies in Health

- Rapid review: Cabozantinib for 2L Renal Cell Carcinoma - [link](#)
- Rapid review: Midline Catheters for Administering Intravenous Infusion Therapy - [link](#)
- Calcitonin Gene-Related Peptide Inhibitors for Migraine Prophylaxis - [link](#)
- Switching Calcitonin Gene-Related Peptide Inhibitors for Migraine Prophylaxis - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)

- Acetylcysteine 200mg Powder for oral solution - adjuvant in the therapy of respiratory disorders associated with thick, viscous, mucus hypersecretion. The contents of one sachet should be emptied into a glass containing 150 ml of water and stirred until it dissolves completely
- Besavar XL (alfuzosin) - contraindicated with concomitant use of ritonavir alone or in combination with ombitasvir/paritaprevir, as alfuzosin blood levels may be increased. Additionally, palpitations, hypotension, flushes and dry mouth added as uncommon adverse reactions
- Efluelda TIV-HD suspension for injection in pre-filled syringe - inactivated, split virion vaccine for active immunisation in adults 60 years of age and older to prevent
- Fortacin (lidocaine, prilocaine) 150 mg/ml + 50 mg/ml Cutaneous spray solution - for the treatment of primary premature ejaculation in adult men
- Lytgobi (futibatinib) tablets - irreversible kinase inhibitor of FGFR 1, 2, 3 & 4, for treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or rearrangement that have progressed after ≥1 prior line of systemic therapy
- Supemtek TIVr solution for injection in pre-filled syringe - recombinant, trivalent influenza vaccine (prepared in cell culture) for active immunization to prevent influenza disease in adults.

European Medicines Agency (EMA)

- Clinical Trials Information System designated as WHO primary registry - [link](#)
- Streamlining development and assessment of biosimilar medicines - [link](#)
- CHMP recommends approval
- acalabrutinib ([Calquence](#)) for adults with previously untreated mantle cell lymphoma
- atropine eye drops ([Ryiunea](#)) to slow progression of myopia in children aged 3-14 years
- bosutinib ([Bosulif](#)) for use in paediatric patients
- dalbavancin ([Xydalba](#)) for use in younger children
- ferric citrate coordination complex ([Xoanacyl](#)) for the treatment of concomitant hyperphosphataemia and iron deficiency in adults with chronic kidney disease (CKD)
- [Flucelvax](#) influenza vaccine for use in younger children
- [guselkumab](#) (Tremfya) for treatment of Crohn's disease
- [nivolumab](#) for neoadjuvant and adjuvant treatment of NSCLC
- subcutaneous formulation of [nivolumab](#) (Opdivo)
- tislelizumab ([Tevimbra](#)) for the treatment of small cell lung cancer (SCLC)
- CHMP negative opinions: donanemab ([Kisunla](#)) for Alzheimer's disease; extension of indication for pemigatinib ([Pemazyre](#)) for myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Food and Drug Administration (FDA) USA

- New Drug approvals
- durvalumab ([Imfinzi](#)) for muscle invasive bladder cancer
- Cabometyx ([cabozantinib](#)) for adults & pediatric patients 12 years + with pNET & epNET
- expands [Pluvicto](#)'s (lutetium Lu 177 vipivotide tetraxetan) metastatic castration-resistant prostate cancer indication
- [Qfitlia](#) (fitusiran) to prevent/reduce the frequency of bleeding episodes in hemophilia A/B - [link](#)
- [Vanrafia](#) (Atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

Medicines and Healthcare products Regulatory Agency (MHRA)

- Approves trofolostat for diagnostic imaging of prostate cancer in men - [link](#)
- Approves eplontersen for adults with rare inherited nerve disease or polyneuropathy - [link](#)
- Approves trastuzumab deruxtecan to treat adults with HER2-positive cancer that has spread or cannot be removed by surgery - [link](#)

Monthly Index of Medical Specialities (MIMS) UK

- Hayfever: clinical review - [link](#)
- First anti-androgen cream, Winlevi (clascoterone), launched in UK for acne - [link](#)

Neonatal & Paediatric Pharmacists Group UK

- Updated Position Statement: Enteral Calcium, Phosphate, Potassium and Zinc Supplementation in Neonates and Children - [link](#)

NHS England

- Interim commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity - [link](#)
- Cardiovascular disease prevention: Lipid management including access to inclisiran - [link](#)
- Nationwide roll out across NHS of artificial intelligence (AI) tool that predicts falls and viruses - [link](#)
- NHS England and NICE genomic testing pathway - [link](#)

NHS Scotland

- Accepted for use:
 - Alectinib ([Alecensa](#)®) as monotherapy for adjuvant treatment of adults with Stage 1B to IIIA anaplastic lymphoma kinase positive NSCLC following complete tumour resection
 - Elafibranor ([Iqirvo](#)®) for primary biliary cholangitis when used in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a monotherapy in adults unable to tolerate UDCA
 - Eplontersen ([Wainzua](#)®) for hereditary transthyretin-mediated amyloidosis in adults with Stage 1 and 2 polyneuropathy, offering an additional treatment choice of transthyretin gene silencer
 - Futibatinib ([Lytgobi](#)®), an additional treatment choice in the therapeutic class of fibroblast growth factor receptor tyrosine kinase inhibitors used to treat adults with locally advanced or metastatic cholangiocarcinoma
- Accepted for restricted use:
 - Bimekizumab ([Bimzelx](#)®) for active moderate to severe hidradenitis suppurativa in patients with an inadequate response to conventional systematic therapy and in whom adalimumab is contraindicated or considered otherwise unsuitable
 - Dapagliflozin ([Forxiga](#)®) as an additional treatment choice within its therapeutic class for the treatment of chronic kidney disease in patients that have individually optimised standard care including an ACEI or ARB unless contra-indicated
- Not recommended:
 - Tebentafusp ([Kimmtrak](#)®) for human leukocyte antigen (HLA)-A*02.01-positive adult patients with unresectable or metastatic uveal melanoma - insufficiently robust economic analysis to support it

National Institute for Health and Care Excellence (NICE) UK

- Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over ([TA1051](#))
- Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B ([HST32](#))
- Burosumab for treating X-linked hypophosphataemia in children and young people ([HST8](#))
- Suspected cancer: recognition and referral - updated ([NG12](#))

National Institute for Health and Care Research (NIHR)

- Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis - [link](#)
- Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map - [link](#)

Royal College of Emergency Medicine

- Advisory Statement: Time Critical Medication Self- Administration in Emergency Departments - [link](#)

Specialist Pharmacy Services NHS UK

- Pain treatment during pregnancy - [link](#)
- Switching between morphine and other opioids in palliative care - [link](#)
- Using potassium permanganate for skin conditions or wound care - [link](#)

UK Health Security Agency

- Antibiotic-resistant gonorrhoea cases rising in England - [link](#)
- Latest update on Clade Ib mpox - [link](#)
- UKHSA launches campaign to tackle misconceptions on antibiotics - [link](#)
- Vaccination against mpox: information for healthcare practitioners - [link](#)

World Health Organisation (WHO)

- Guidance on mental health policy and strategic action plans - [link](#)
- WHO issues its first-ever reports on tests and treatments for fungal infections - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)

- Adacel (diphtheria, tetanus and pertussis vaccine) suspension for injection in pre-filled syringe - normal appearance is a uniform, cloudy, white suspension, which may sediment and form clumpy or flaky aggregates during storage. Syringe should be shaken well to uniformly distribute suspension before administering vaccine
- Bosulif (bosutinib) - recommendation to monitor patients for signs and symptoms consistent with cardiac failure and cardiac ischaemia and treated as clinically indicated, noting cardiotoxicity can be managed by dose interruption, dose reduction and/or discontinuation
- Doxorubicin Solution for Injection (Pfizer) - women should use two effective contraception methods during treatment and for ≥ 7 months after last dose, and men during treatment and for ≥ 4 months after last dose. Women should not breastfeed during and for at least 10 days after last dose
- Drovelis (drospirenone/ estetrol) contraindicated in women with severe renal impairment and not recommended in women with moderate renal impairment. No dose adjustment is required in women with mild renal impairment
- Durogesic DTrans (fentanyl) Transdermal - new contraindication of acute or post-operative pain because there is no opportunity for dose titration during short-term use, and because serious or life-threatening hypoventilation or persistent post-operative opioid use could result influenza.
- Evrenzo (roxadustat) - thrombocytopenia included as common ADR
- Fragmin (dalteparin) - hyperkalaemia as a potential ADR of treatment (frequency: common).
- Glyxambi - phimosis/acquired phimosis (tight foreskin) reported concurrent with genital infections, and in some cases, circumcision was required. Also updated with additional info on prolonged ketoacidosis and prolonged glucosuria, as well as elevated haematocrit
- Oxlumo (lumasiran) - hypersensitivity as an ADR (frequency unknown) reported during post-marketing use
- Rezero (belumosudil) Predicted to increase theophylline levels by 40%. Caution also advised when co-administering with other CYP1A2 substrates such as warfarin, tizanidine or pomalidomide
- Rybelsus (semaglutide) - should be taken after a recommended fasting period of at least 8 hours

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Sitagliptin/Metformin - metformin is not recommended in patients with known or suspected mitochondrial diseases, due to the risk of lactic acidosis exacerbation and neurologic complications which may lead to worsening of the disease
- Steglatro (ertugliflozin) - rash added as a new ADR of unknown frequency
- Risk minimisation materials
- AbbVie: [Duodopa](#) (levodopa, carbidopa monohydrate) intestinal gel - guide for healthcare professionals provides information on recommended measures to minimise gastrointestinal, gastrointestinal device, and gastrointestinal procedure related events. A patient guide is also available
- Neon Healthcare: [Roaccutane](#) (isotretinoin) - Materials include a checklist for pharmacists dispensing oral isotretinoin, regarding the contraindication for its use in pregnancy, an acknowledgement of risk form, and a patient reminder card on pregnancy risks and mental health

EMA

- European Medicines Agency concludes review of weight management medicine Mysimba (naltrexone / bupropion) - [link](#)

Health Canada – MedEffect Notice

- Health Product InfoWatch, [March 2025](#) includes:
 - Monthly recap: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide); Isotretinoin; Lacosamide Injection, USP; Oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban and warfarin)
 - Review article: Systemic fluoropyrimidines and severe toxicity in patients with dihydropyrimidine dehydrogenase deficiency

Medicines and Healthcare products Regulatory Agency (MHRA) UK

- MHRA Safety Roundup: [March 2025](#) includes:
 - Prolonged-release opioids: Removal of indication for relief of post-operative pain

Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

- Ayurvedic medicines update - [link](#)

MIMS monthly updates

- New Contraindications
 - Metronidazole ([Flagyl](#)) is now contraindicated in patients with Cockayne syndrome
 - Obeticholic acid ([Ocaliva](#)) is now contraindicated in patients with compensated cirrhosis who have evidence of portal hypertension (e.g. ascites, gastroesophageal varices, persistent thrombocytopenia)

Specialist Pharmacy Services NHS UK

- ACEI suggestions for adults with swallowing difficulties - [link](#)
- Using contraception with enzyme-inducing medicines - [link](#)

TGA

- Further shortage of methylphenidate hydrochloride products - [link](#)
- New safety warnings for isotretinoin ([Roaccutane](#)) - [link](#)
- Product Information safety updates - [March 2025](#)
- NAD, NAD+, NADH or NMN medicines sold in Australia - [link](#)
- Magnum XXL capsules - [link](#)
- Counterfeit Ozempic injection pens detected - [link](#)
- Product Alert: Vyvanse capsules multiple strength - [link](#)
- Recall: Multiple vitamin and perinatal products - [link](#)

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)

- The impact of a customized electronic health record clinical decision support tool on pharmacist renal dosing interventions - [link](#)
- Cabotegravir/rilpivirine resistance in a patient living with HIV despite on-time administration: A case report - [link](#)

American Journal of Medical Quality

- A Checklist to Improve Acute Stroke Evaluation and Treatment in the Emergency Department - [link](#)

Annals of Internal Medicine

- National Trends in Glucagon-Like Peptide-1 Receptor Agonist Use in Adults Without Diabetes, 2018 to 2022 - [link](#)
- Comparison of Dose Escalation Versus Switching to Tirzepatide Among People with Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide: A Randomized Clinical Trial - [link](#)
- Cannabis or Cannabinoids for the Management of Chronic Noncancer Pain: Best Practice Advice From the American College of Physicians - [link](#)
- U.S. Emergency Department Visits Attributed by Clinicians to Semaglutide Adverse Events, 2022–2023 - [link](#)
- In the clinic: Epilepsy - [link](#)

Arthritis & Rheumatology

- Clinical factors associated with pneumocystis pneumonia despite its primary prophylaxis: When to stop prophylaxis? - [link](#)
- Recurrence Risk in Pediatric Non-Infectious Uveitis during Adalimumab Tapering: An International Multicenter Retrospective Study - [link](#)

British Journal of Clinical Pharmacology

- Education about deprescribing for pre-licensed and licensed healthcare professionals: A scoping review - [link](#)
- Best fit framework synthesis of qualitative studies on factors associated with medication nonadherence in people with type 2 diabetes using the COM-B model - [link](#)
- Incidence and spectrum of typical complications associated with immunosuppressant use in rheumatic disease: A nationwide retrospective study - [link](#)
- EudraVigilance insights: Suspected adverse drug reactions in infants through breastfeeding - [link](#)
- The impact of early-life and prolonged antibiotics exposure on 78 common diseases: Evidence from epidemiology - [link](#)

British Journal of General Practice

- GLP-1 receptor agonists: panacea or affirmation of societal failure? - [link](#)

British Journal of Psychiatry

- Systematic review of the efficacy of pharmacological and non-pharmacological interventions for improving quality of life of people with dementia - [link](#)
- Missing a trick? Bupropion for the pharmacological treatment of depression in the UK - [link](#)
- Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: network meta-analysis - [link](#)

British Medical Journal (BMJ)

- Stepwise dual antiplatelet therapy de-escalation in patients after drug coated balloon angioplasty (REC-CAGEFREE II): multicentre, randomised, open label, assessor blind, non-inferiority trial - [link](#)
- Tuberculosis in the UK - [link](#)
- Practice Pointer: Caring for patients experiencing homelessness - [link](#)
- How tariffs are likely to detrimentally affect global medicine supply chains - [link](#)
- Evaluating patients with chest pain in the emergency department - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Finding the right treatment for severe depression - [link](#)

BMJ Open

- Vitamin D supplementation for managing COVID-19 in patients with vitamin D deficiency: a systematic review and meta-analysis of randomised controlled trials - [link](#)
- Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis - [link](#)
- Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System - [link](#)

Cochrane

- Withdrawal of antihypertensive drugs in older people - [link](#)
- Effect of amphetamines on blood pressure - [link](#)
- Mucolytics for children with chronic suppurative lung disease - [link](#)
- Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis - [link](#)
- Effect of adrenergic agonist oral decongestants on blood pressure - [link](#)
- Multimodal interventions for cachexia management - [link](#)
- Delayed initiation or reduced initial dose of calcineurin-inhibitors for kidney transplant recipients at high risk of delayed graft function - [link](#)
- Drug treatment for myotonia - [link](#)
- Gonadotropins for ovulation induction in women with polycystic ovary syndrome - [link](#)
- Preoperative medical therapy before surgery for uterine fibroids – [link](#)
- Transversus abdominis plane (TAP) blocks for prevention of postoperative pain in women undergoing laparoscopic and robotic gynaecological surgery - [link](#)
- Stem cell injections for osteoarthritis of the knee - [link](#)

Diabetes Care

- Association Between Use of Sodium–Glucose Cotransporter 2 Inhibitors and Epilepsy: A Population-Based Study Using Target Trial Emulation - [link](#)
- Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectible and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials - [link](#)
- Risk of Urogenital Infections in People With Type 2 Diabetes Initiating SGLT2i Versus GLP-1RA in Routine Clinical Care: A Danish Cohort Study - [link](#)

Diabetic Medicine

- Extended use of real-time continuous glucose monitoring in adults with insulin-requiring type 2 diabetes: Results from the first 26 weeks of the 2GO-CGM trial - [link](#)

Drug and Therapeutics Bulletin

- Initiating renin–angiotensin system inhibitors in chronic kidney disease - [link](#)

EClinical Medicine

- Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysis - [link](#)

European Heart Journal

- Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study - [link](#)

European Journal of Hospital Pharmacy

- Improving patient outcomes during cancer drug shortages: the role of patient education - [link](#)

Heart

- Long-term benefits of atorvastatin on the incidence of cardiovascular events: the ASCOT-Legacy 20-year follow-up - [link](#)
- Inflammation in coronary atherosclerosis: diagnosis and treatment - [link](#)

Internal Medicine Journal

- Impact of sulfonamide allergy label on clinical outcomes of acute cystitis: a retrospective matched cohort study - [link](#)
- Vulnerability of a New Zealand hospital computerised provider order entry system to prescribing error: a comparative study with other systems - [link](#)
- Advancements in multiple sclerosis - [link](#)
- Letter: Short course antiviral therapy to prevent donor-derived hepatitis C virus infection - [link](#)
- Letter: Rapid desensitisation therapy in a patient with furosemide-induced anaphylactic shock: a case report and short-term follow-up - [link](#)
- Letter: Cardiac medication non-adherence: the elephant in the room - [link](#)

International Journal of Clinical Pharmacy

- Drug-related problems experienced by rheumatoid arthritis patients during the first three months of methotrexate use: a longitudinal observational study - [link](#)
- Streamlining the quality assessment in medication reviews: a biased random sampling approach using BRANT-MERQS criteria - [link](#)
- Application of a screening tool to understand the medication habits of patients with swallowing difficulty: a prospective observational study - [link](#)

JAMA

- Long-Term Risk of Stroke After Transient Ischemic Attack or Minor Stroke: A Systematic Review and Meta-Analysis - [link](#)
- Patient page: What Is Carbon Monoxide Poisoning? - [link](#)
- Intravenous Ferric Carboxymaltose in Heart Failure with Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial - [link](#)
- Iron Deficiency in Adults: A Review - [link](#)
- Reported psychiatric adverse events among isotretinoin users: Monitoring priorities from a 20-year FDA Adverse Event Reporting System database study - [link](#)
- Small Cell Lung Cancer: A Review - [link](#)
- Management of Staphylococcus aureus Bacteremia: A Review - [link](#)

JAMA Cardiology

- Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial - [link](#)
- Encouraging Pharmacist Referrals for Evidence-Based Statin Initiation: Two Cluster Randomized Clinical Trials - [link](#)

JAMA Internal Medicine

- Inclusion of Retracted Studies in Systematic Reviews and Meta-Analyses of Interventions: A Systematic Review and Meta-Analysis - [link](#)
- Risk of Major Congenital Malformations Following Prenatal Exposure to Smoking Cessation Medicines - [link](#)
- Change in Default Prescription Length and Statin Prescribing Behavior - [link](#)
- Hospital Addiction Consultation Service and Opioid Use Disorder Treatment The START Randomized Clinical Trial - [link](#)
- Mortality among veterans with opioid use disorder after medical hospitalisation - [link](#)

JAMA Neurology

- N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy: A Nonrandomized Clinical Trial - [link](#)
- Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response-Adaptive Randomized Clinical Trial - [link](#)
- Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis - [link](#)
- Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis - [link](#)
- GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias - [link](#)

JAMA Oncology

- Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma: A Review - [link](#)

JAMA Ophthalmology

- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients with Diabetes - [link](#)

Joint Commission Journal on Quality and Patient Safety

- Using Implementation Science-Informed Strategies to Improve Transitions of Care for Patients with Venous Thromboembolism - [link](#)
- Safety Interventions in Cardiac Anesthesia: A Systematic Review - [link](#)

Journal of Sleep Research

- A randomised crossover trial of daridorexant for the treatment of chronic insomnia and nocturia - [link](#)

Lancet

- Pancreatic cancer - [link](#)

Lancet Diabetes & Endocrinology

- Futility of plasmapheresis, insulin in normoglycaemic individuals, or heparin in the treatment of hypertriglyceridaemia-induced acute pancreatitis - [link](#)

Lancet Gastroenterology and Hepatology

- Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design - [link](#)

Lancet Haematology

- A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial - [link](#)

Lancet HIV

- HIV seropositivity and viral non-suppression in transgender, non-binary, and gender-diverse people in primary care receiving gender-affirming hormone therapy in the USA between 2013 and 2019 (LEGACY): an observational, longitudinal, cohort study - [link](#)
- Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial - [link](#)

Lancet Infectious Diseases

- Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Efficacy and safety of individualised versus standard 10-day antibiotic treatment in children with febrile urinary tract infection (INDI-UTI): a pragmatic, open-label, multicentre, randomised, controlled, non-inferiority trial in Denmark - [link](#)
- Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies - [link](#)

Lancet Oncology

- Innovative, early-phase clinical trials of drug–radiotherapy combinations - [link](#)
- Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee - [link](#)
- New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis - [link](#)

Lancet Psychiatry

- INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia - [link](#)
- Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis - [link](#)

Lancet Regional Health (Europe)

- 2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies - [link](#)
- Paramedic analgesia comparing ketamine and morphine in trauma (PACKMaN): a randomised, double-blind, phase 3 trial - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- Impact of Removing Race Coefficient from Glomerular Filtration Rate Estimation Equations on Antidiabetics Among Black Patients - [link](#)

Medical Journal of Australia

- Perspective: Dismantling barriers to research and clinical care for individuals with a vision impairment - [link](#)
- Editorial: Pills, profits, and pollution: accountability for pharmaceuticals-related greenhouse gas emissions - [link](#)
- Accountability, ambition, and quantifiable action in the carbon emission reduction plans of the ten largest pharmaceutical companies in Australia: a cross-sectional analysis - [link](#)

Nature Medicine

- Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial - [link](#)

New England Journal of Medicine

- Unexplained or Refractory Chronic Cough in Adults - [link](#)
- Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation - [link](#)
- Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism - [link](#)
- Global Effect of Cardiovascular Risk Factors on Lifetime Estimates - [link](#)
- Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) - [link](#)
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes - [link](#)
- Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death - [link](#)
- A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis - [link](#)
- Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours - [link](#)
- Left Atrial Appendage Closure after Ablation for Atrial Fibrillation - [link](#)
- Malaria - [link](#)

Pediatrics (American Academy of Pediatrics)

- Monoclonal Antibodies for Pediatric Viral Disease Prevention and Treatment - [link](#)

Pharmaceutical Journal

- Medicines derived from UK blood plasma distributed to NHS hospitals for 'first time in a generation' - [link](#)

Pharmacotherapy

- Updates in chronic kidney disease management: A systematic review - [link](#)
- Pharmacokinetic approaches to standardize antiviral exposure in cerebrospinal fluid - [link](#)

PLOS Medicine

- Pharmacogenetics and adverse drug reports: Insights from a United Kingdom national pharmacovigilance database - [link](#)

Prescribe International [April 2025](#) includes

- Esketamine (Spravato®) in depression after failure of several antidepressants or with a high risk of suicide?
- SSRI antidepressants and venlafaxine: increased risk of injuries
- Editorial: Metamizole (also known as dipyrone) is an analgesic and antipyretic drug that exposes patients to a risk of fatal agranulocytosis of unpredictable onset

Thorax

- Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC) - [link](#)

CONSULTATIONS (new additions in bold)

Agency for Clinical Innovation, NSW (ACI)

- Consultation: Choices for kidney failure treatment, closes 23 May 2025 - [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 185](#) – The role of triple antithrombotic therapy in patients with atrial fibrillation and coronary stent insertion

UPCOMING EVENTS

EACPT

- 17th Congress of the European Association for Clinical Pharmacology and Therapeutics, 28 June – 1 July, Helsinki, Finland - [register](#)

Australian Centre for Value-Based Health Care

- 2025 Congress: Partnering to advance VBHC in Australia, 1-2 May 2025, Melbourne - [register](#)

NHMRC Medicines Intelligence Centre of Research Excellence (MI-CRE)

- Fifth Annual Research Symposium: Better together: advancing medicines intelligence through partnerships, 29-30 October 2025, UNSW Sydney - abstracts emailed to mi-cre@unsw.edu.au by Friday 8 August 2025